KOL Corner: Amy Ellis Discusses Value-Based Cancer Rehab With Amanda Hodges

Amy Ellis, director of quality and value-based care at Northwest Medical Specialties, and Amanda Hodges, director of implementation for ReVital Cancer Rehabilitation, who acts as a bridge between the oncology world and the rehabilitation world, discuss overcoming barriers in practices to help patients with cancer get the rehab care they need, how patients with cancer can benefit from rehab, and defining value.

Related Videos

Related Content

Advertisement

April 30th 2025

Assessing the Complex Interplay Between Metabolic Dysfunction and Rheumatoid Arthritis

Jared Kaltwasser

Many studies have examined how rheumatoid arthritis therapy affects the risk of metabolic comorbidities.

April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD

On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.

April 29th 2025

Study Highlights Unmet Needs in Measuring Patient Experiences in Alopecia Areata

Cameron Santoro

Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported outcome measures (PROMs) specific to alopecia areata (AA), a common hair loss condition with substantial quality of life impacts.

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

April 29th 2025

Loneliness Poses a Clinical Risk for Patients With Chronic Illness

Kyle Munz

A new survey highlights how the mental toll of loneliness trickles down to have very real physical consequences for patients with chronic illness.

April 29th 2025

FDA Approves Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa

Rose McNulty

Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with recessive dystrophic epidermolysis bullosa.

Related Content

Advertisement

April 30th 2025

Assessing the Complex Interplay Between Metabolic Dysfunction and Rheumatoid Arthritis

Jared Kaltwasser

Many studies have examined how rheumatoid arthritis therapy affects the risk of metabolic comorbidities.

April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD

On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.

April 29th 2025

Study Highlights Unmet Needs in Measuring Patient Experiences in Alopecia Areata

Cameron Santoro

Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported outcome measures (PROMs) specific to alopecia areata (AA), a common hair loss condition with substantial quality of life impacts.

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

April 29th 2025

Loneliness Poses a Clinical Risk for Patients With Chronic Illness

Kyle Munz

A new survey highlights how the mental toll of loneliness trickles down to have very real physical consequences for patients with chronic illness.

April 29th 2025

FDA Approves Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa

Rose McNulty

Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with recessive dystrophic epidermolysis bullosa.